

Case Report

Open Access

***EGFR C797S* as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with *EGFR T790M* Mutation**

Sehhoon Park, MD¹
Bo Mi Ku, PhD²
Hyun Ae Jung, MD, PhD¹
Jong-Mu Sun, MD, PhD¹
Jin Seok Ahn, MD, PhD¹
Se-Hoon Lee, MD, PhD¹
Keunchil Park, MD, PhD¹
Myung-Ju Ahn, MD, PhD¹

¹Division of Hematology-Oncology,
 Department of Medicine,

²Samsung Biomedical Research Institute,
 Samsung Medical Center, Sungkyunkwan
 University School of Medicine, Seoul, Korea

Correspondence: Myung-Ju Ahn, MD, PhD
 Division of Hematology-Oncology,
 Department of Medicine, Samsung Medical
 Center, Sungkyunkwan University School of
 Medicine, 81 Irwon-ro, Gangnam-gu,
 Seoul 06351, Korea
 Tel: 82-2-3410-3438
 Fax: 82-2-3410-1754
 Email: silkahn@skku.edu

Received April 5, 2020
 Accepted June 19, 2020
 Published Online June 22, 2020

The non-small cell lung cancer with activating epidermal growth factor receptor (*EGFR*) mutation eventually acquires resistant to either first or second-generation *EGFR* tyrosine kinase inhibitor (TKI). As the following option, targeting *EGFR T790M* with third-generation *EGFR* TKI is now established as a standard treatment option. In this study, we are reporting the first case of resistance mechanism to the novel third-generation *EGFR* TKI, lazertinib, which showed promising clinical efficacy in phase 1-2 study. The patients showed resistance to the treatment by acquiring the additional *EGFR C797S* mutation in cis which is also confirmed from the patient-derived cell lines.

Key words

Non-small cell lung cancer, Lazertinib, Third-generation *EGFR* tyrosine kinase inhibitor, ErbB receptors

Introduction

Non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (*EGFR*) mutation treated with either a first- or second-generation tyrosine kinase inhibitor (TKI) can experience treatment failure, most commonly by acquiring an additional genomic alteration in *EGFR T790M* [1]. Lazertinib (YH25448) is a potent irreversible third-generation *EGFR* TKI that targets both *T790M* and activating *EGFR* mutation with high penetration to the blood-brain barrier. Lazertinib showed promising anti-tumor efficacy with a 57% overall response rate and 9.7-month median progression-free survival in *EGFR T790M*-positive patients [2]. However, there is no previous report showing the mechanism of tumor resist-

ance acquisition to lazertinib. In this case report, we conducted deep-targeted sequencing of resistant tumor samples and established patient-derived cell lines (PDC) from a patient treated with lazertinib to elucidate the underlying genomic alteration associated with resistance.

Case Report

A 38-year-old current male smoker presented with stage 4, cT1bN3M1b, NSCLC adenocarcinoma. Informed consent was received under supervision of institutional review board (SMC 2011-10-054-034). The patient was shown to harbor an *EGFR* exon 19 deletion using real-time polymerase chain




Fig. 1. (A) Target sequencing in samples from lazertinib-resistant malignant ascites. Integrative genomic viewer of sample showing additional epidermal growth factor receptor (*EGFR*) C797S cis mutation. (B) Western blot of patient-derived cell line (PDC) samples. (C) Cell viability analyses conducted in samples after exposure to tyrosine kinase inhibitor for 72 hours. SNV, single nucleotide variant; INDEL, insertion/deletion; EpCAM, epithelial cell adhesion molecule.

reaction from the initial biopsy sample obtained from the mediastinal lymph node. Afatinib was administered as a first-line treatment and showed very good partial response with 7.1 months of progression-free survival. After first-line EGFR TKI failure, a second biopsy from the newly progressed metastatic lymph node showed acquired *EGFR* T790M mutation.

As a subsequent treatment, the patient received lazertinib as a part of a clinical trial (NCT03046992, YH25448-201). However, after 6.2 months of partial response to lazertinib, the patient developed malignant ascites, suggesting peritoneal seeding due to resistance.

Deep-targeted sequencing (CancerSCAN [3]) of ascites

samples demonstrated acquired *EGFR* C797S mutation *in cis*, variant allele frequency (VAF) of 9.4%, *EGFR* T790M (VAF of 3.5%), and *EGFR* exon 19 deletion (VAF 9.2%) (Fig. 1A). PDCs established from the same ascites sample showed *EGFR* exon 19 deletion (Fig. 1B). Cell viability of PDCs showed resistance to first- and third-generation *EGFR* TKIs including erlotinib, gefitinib, lazertinib, and osimertinib or the c-Met inhibitor savolitinib (Fig. 1C).

Discussion

Diverse resistance mechanisms to third-generation *EGFR* TKI have been reported including loss of T790M, acquisition

of *EGFR* C797S mutation, c-Met amplification, activation of other bypass tract, or small cell lung cancer transformation. Among them, *EGFR* C797S/T790M mutation is the most frequently observed, accounting for 20%-30% of cases. It is of note that tumors acquiring an additional mutation of *EGFR* C797X maintain the original *EGFR* T790M mutation [4]. In this report, we present the first clinical case of new *EGFR* C797S/T790M mutation in a patient who failed lazertinib. Further validation with a large number of patients and new treatment strategies to overcome this resistance mutation are warranted.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

References

1. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to *EGFR* inhibitors. *Sci Transl Med*. 2011;3:75ra26.
2. Ahn MJ, Han JY, Lee KH, Kim SW, Kim DW, Lee YG, et al. Lazertinib in patients with *EGFR* mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. *Lancet Oncol*. 2019;20:1681-90.
3. Shin HT, Choi YL, Yun JW, Kim NK, Kim SY, Jeon HJ, et al. Prevalence and detection of low-allele-fraction variants in clinical cancer samples. *Nat Commun*. 2017;8:1377.
4. Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, et al. Assessment of resistance mechanisms and clinical implications in patients with *EGFR* T790M-positive lung cancer and acquired resistance to osimertinib. *JAMA Oncol*. 2018;4:1527-34.